Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function
Life Science Alliance · 2024
DOI: 10.26508/lsa.202402671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Sophie Bromberger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Melanoma, Signal Transduction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vienna Science and Technology Fund, Comprehensive Cancer Center Vienna, European Molecular Biology Organization.
Abstract (Originalsprache)
Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with dabrafenib or encorafenib. Together, these findings provide insights into the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Medical University of Vienna, Vienna, Austria.
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
- University of Applied Sciences FH Campus Wien, Division of Biomedical Science, Vienna, Austria.
- Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria.
- Department of Dermatology, Medical University of Vienna, Vienna, Austria klaudia.schossleitner@meduniwien.ac.at.
ORCID-Profile: Sophie Bromberger, Julia Maria Ressler, Silvio Holzner, Nina Zila, Alexander Springer, Martin Røssel Larsen, Klaudia Schossleitner
Förderung
- Vienna Science and Technology Fund
- Comprehensive Cancer Center Vienna
- European Molecular Biology Organization
- City of Vienna, Cancer Research Fund
Zitieren
APA
Bromberger, S., Zadorozhna, Y., Ressler, J. M., Holzner, S., Nawrocki, A., Zila, N., Springer, A., Røssel Larsen, M., & Schossleitner, K. (2024). Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. Life Science Alliance. https://doi.org/10.26508/lsa.202402671
Vancouver
Bromberger S, Zadorozhna Y, Ressler JM, Holzner S, Nawrocki A, Zila N, et al. Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. Life Science Alliance. 2024. doi:10.26508/lsa.202402671
BibTeX
@article{Bromberger2024,
author = {Bromberger, Sophie and Zadorozhna, Yuliia and Ressler, Julia Maria and Holzner, Silvio and Nawrocki, Arkadiusz and Zila, Nina and Springer, Alexander and Røssel Larsen, Martin and Schossleitner, Klaudia},
title = {Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function},
journal = {Life Science Alliance},
year = {2024},
doi = {10.26508/lsa.202402671}
}
EUVIMED